Precision Therapeutics (NASDAQ:POAI) Upgraded by ValuEngine to Buy

ValuEngine upgraded shares of Precision Therapeutics (NASDAQ:POAI) from a hold rating to a buy rating in a research note released on Tuesday, ValuEngine reports.

POAI traded up $0.01 during trading on Tuesday, hitting $3.01. 48,013 shares of the stock were exchanged, compared to its average volume of 12,385. The company has a quick ratio of 0.08, a current ratio of 0.10 and a debt-to-equity ratio of 0.02. Precision Therapeutics has a 1-year low of $2.35 and a 1-year high of $11.50. The company’s fifty day simple moving average is $2.94.

An institutional investor recently bought a new position in Precision Therapeutics stock. Vanguard Group Inc. bought a new position in shares of Precision Therapeutics Inc (NASDAQ:POAI) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 155,934 shares of the medical instruments supplier’s stock, valued at approximately $115,000. Vanguard Group Inc. owned about 0.51% of Precision Therapeutics at the end of the most recent quarter. Institutional investors and hedge funds own 10.89% of the company’s stock.

About Precision Therapeutics

Predictive Oncology Inc provides various healthcare products and services primarily in the United States. The company manufactures environmentally conscious systems for the collection and disposal of infectious fluids that result from surgical procedures and post-operative care. It offers the STREAMWAY Fluid Waste Management system that suctions surgical waste fluid from the patient using standard surgical tubing; and disposables.

Featured Article: Initial Coin Offerings entail a high degree of risk

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Precision Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precision Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.